SequelSEC

BIOLARGO, INC. BLGO

Chemicals & Allied Products · CIK 0000880242 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$1.25M
Fiscal year ended 2026-06-30
Operating income
-$3.73M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$63.07MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.20Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue8.1×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity41.3×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Chemicals & Allied Products filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio1.01x0th
Revenue YoY growth-56.3%7th
Gross margin43.9%93th
R&D / revenue33.4%90th
SBC / revenue38.2%86th
Operating margin-191.3%17th

BIOLARGO, INC. (BLGO) reported revenue of $1.25M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from BIOLARGO, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Chemicals & Allied Products.

Income

BIOLARGO, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$1.25M$1.12M$617.00K$1.10M$2.78M$3.27M$3.66M$4.35M$5.01M$4.76M
Cost of revenue$573.00K$657.00K$489.00K$731.00K$1.36M$1.78M$1.91M$2.63M$2.88M$2.51M
Gross profit$675.00K$458.00K$128.00K$372.00K$1.42M$1.49M$1.75M$1.72M$2.14M$2.25M
Operating income-$3.73M-$3.20M-$4.01M-$7.18M-$1.80M-$1.86M-$1.62M-$1.06M-$890.00K-$763.00K
Net incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Research & development$1.09M$907.00K$659.00K$615.00K$535.00K$791.00K$784.00K$690.00K$623.00K$784.00K
Weighted-average diluted sharesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPSUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrative$3.32M$2.76M$3.43M$3.09M$2.69M$2.52M$2.58M$2.09M$2.40M$2.22M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

BIOLARGO, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$2.19M$4.12M$3.88M$4.55M$3.47M$2.56M$3.55M$3.88M$4.76M$4.34M
Total assets$6.67M$8.56M$8.31M$9.13M$12.50M$10.51M$10.51M$10.30M$10.05M$9.82M
Current assets$3.50M$5.44M$5.11M$5.78M$9.19M$7.22M$7.14M$7.39M$7.11M$7.18M
Total liabilities$9.40M$8.75M$6.78M$5.92M$6.44M$5.42M$4.46M$4.32M$4.16M$4.67M
Current liabilities$4.76M$4.93M$5.06M$3.45M$4.08M$3.37M$2.65M$3.20M$3.01M$3.40M
Total equity incl. NCI-$2.73M-$187.00K$1.53M$3.22M$6.06M$5.09M$6.06M$5.98M$5.89M$5.15M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$303.00K$292.00K$310.00K$409.00K$444.00K$369.00K$330.00K$238.00K$176.00K$251.00K
Accounts receivable$724.00K$730.00K$615.00K$761.00K$1.74M$4.21M$3.17M$3.21M$2.10M$2.47M
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailable$2.08MUnavailableUnavailableUnavailable$1.08M$180.00K$184.00K$284.00K
Accounts payable$874.00K$838.00K$1.01M$789.00K$1.18M$1.15M$826.00K$1.56M$1.47M$1.66M

Cash flow

BIOLARGO, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$3.06M-$2.92M-$1.59M-$2.76M-$2.12M-$1.83M-$1.92M-$1.62M-$151.00K$481.00K
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flow-$160.00K-$32.00K-$13.00K$256.00K$192.00K$0-$57.00K-$39.00K-$358.00K-$863.00K
Financing cash flow$1.28M$3.19M$952.00K$3.57M$2.83M$866.00K$1.59M$764.00K$999.00K$1.08M
Net change in cash-$1.93M$239.00K-$663.00K$1.08M$907.00K-$984.00K-$334.00K-$883.00K$429.00K$797.00K
Stock-based compensation$722.00K$699.00K$1.01M$844.00K$492.00K$615.00K$799.00K$237.00K$539.00K$488.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

BIOLARGO, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross margin54.1%41.1%20.7%33.7%51.2%45.5%47.9%39.6%42.6%47.2%
Operating margin-298.7%-287.4%-650.1%-651.0%-64.9%-57.0%-44.2%-24.4%-17.8%-16.0%
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenue57.9%62.7%164.3%76.5%17.7%18.8%21.8%5.4%10.7%10.3%
Current ratio0.73x1.10x1.01x1.67x2.25x2.14x2.70x2.31x2.36x2.11x
Revenue YoY growth-55.1%-65.9%-83.1%-74.6%-44.6%-31.3%-16.3%62.8%246.7%27.2%
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenue87.2%81.3%106.8%55.8%19.3%24.2%21.4%15.9%12.4%16.5%
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BLGO in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-04View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.